Sharma A, Muralitharan M, Ramage J, Clement D, Menon K, Srinivasan P
Curr Oncol Rep. 2024; 26(9):1070-1084.
PMID: 38869667
PMC: 11416395.
DOI: 10.1007/s11912-024-01559-w.
Han L, Li J, Liang C, Chu Y, Wang Y, Lv L
Surg Endosc. 2024; 38(4):2041-2049.
PMID: 38429572
DOI: 10.1007/s00464-024-10706-0.
Valian H, Emami M, Heidari A, Amjadi E, Fahim A, Lalezarian A
Prev Med Rep. 2023; 36:102468.
PMID: 37869540
PMC: 10587514.
DOI: 10.1016/j.pmedr.2023.102468.
Kupietzky A, Dover R, Mazeh H
World J Gastrointest Surg. 2023; 15(4):566-577.
PMID: 37206065
PMC: 10190731.
DOI: 10.4240/wjgs.v15.i4.566.
Zhang D, Lu L, Zhu H, Xiao Y, Han X, Du S
Int J Endocrinol. 2022; 2022:6283706.
PMID: 35265125
PMC: 8901294.
DOI: 10.1155/2022/6283706.
Multimodal Management of Grade 1 and 2 Pancreatic Neuroendocrine Tumors.
Marchese U, Gaillard M, Pellat A, Tzedakis S, Ali E, Dohan A
Cancers (Basel). 2022; 14(2).
PMID: 35053593
PMC: 8773540.
DOI: 10.3390/cancers14020433.
Role of Resection of the Primary in Metastatic Well-Differentiated Neuroendocrine Tumors.
Shaib W, Zakka K, Penley M, Jiang R, Akce M, Wu C
Pancreas. 2022; 50(10):1382-1391.
PMID: 35041337
PMC: 10848811.
DOI: 10.1097/MPA.0000000000001936.
Paraneoplastic Cushing Syndrome in Gastrointestinal Neuroendocrine Tumour.
Mineur L, Boustany R, Vazquez L
Case Rep Oncol. 2021; 14(3):1407-1413.
PMID: 34720949
PMC: 8525292.
DOI: 10.1159/000518316.
Time from first tumor manifestation to diagnosis in patients with GEP-NET: Results from a large German tertiary referral center.
Koch C, Koca E, Filmann N, Husmann G, Bojunga J
Medicine (Baltimore). 2021; 100(37):e27276.
PMID: 34664885
PMC: 8448036.
DOI: 10.1097/MD.0000000000027276.
Update on Incidence, Prevalence, Treatment and Survival of Patients with Small Bowel Neuroendocrine Neoplasms in the Netherlands.
Kacmaz E, Sarasqueta A, van Eeden S, Dreijerink K, Klumpen H, Tanis P
World J Surg. 2021; 45(8):2482-2491.
PMID: 33895862
PMC: 8236032.
DOI: 10.1007/s00268-021-06119-y.
Evolution of the Mesenteric Mass in Small Intestinal Neuroendocrine Tumours.
Blazevic A, Brabander T, Zandee W, Hofland J, Franssen G, van Velthuysen M
Cancers (Basel). 2021; 13(3).
PMID: 33503893
PMC: 7865677.
DOI: 10.3390/cancers13030443.
Surgical treatment for gastrointestinal neuroendocrine tumors.
Eto K, Yoshida N, Iwagami S, Iwatsuki M, Baba H
Ann Gastroenterol Surg. 2020; 4(6):652-659.
PMID: 33319155
PMC: 7726685.
DOI: 10.1002/ags3.12396.
Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment.
Si Y, Guan J, Xu Y, Chen K, Kim S, Zhou L
Pharmaceutics. 2020; 12(11).
PMID: 33187322
PMC: 7696983.
DOI: 10.3390/pharmaceutics12111079.
Gastrointestinal neuroendocrine tumors in 2020.
Ahmed M
World J Gastrointest Oncol. 2020; 12(8):791-807.
PMID: 32879660
PMC: 7443843.
DOI: 10.4251/wjgo.v12.i8.791.
THE ROLE OF CONVENTIONAL ECHOENDOSCOPY (EUS) IN THERAPEUTIC DECISIONS IN PATIENTS WITH NEUROENDOCRINE GASTROINTESTINAL TUMORS.
Costa R, Kemp R, Dos Santos J, Costa D, Ardengh J, Ribas-Filho J
Arq Bras Cir Dig. 2020; 33(2):e1512.
PMID: 32844878
PMC: 7448866.
DOI: 10.1590/0102-672020190001e1512.
Oncological management of advanced neuroendocrine tumours (Review).
Gut P
Mol Clin Oncol. 2020; 13(3):8.
PMID: 32754322
PMC: 7391839.
DOI: 10.3892/mco.2020.2078.
A side-by-side evaluation of [F]FDOPA enantiomers for non-invasive detection of neuroendocrine tumors by positron emission tomography.
Narayan A, Yan Y, Lisok A, Brummet M, Pomper M, Lesniak W
Oncotarget. 2019; 10(56):5731-5744.
PMID: 31645896
PMC: 6791383.
DOI: 10.18632/oncotarget.27184.
Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors.
Sansone A, Lauretta R, Vottari S, Chiefari A, Barnabei A, Romanelli F
Cancers (Basel). 2019; 11(8).
PMID: 31382663
PMC: 6721814.
DOI: 10.3390/cancers11081113.
The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma.
Yoon S, Kim J, Lee S, Lee J, Park S, Park J
J Cancer. 2019; 10(14):3140-3144.
PMID: 31289584
PMC: 6603380.
DOI: 10.7150/jca.30355.
A case report on metastatic ileal neuroendocrine neoplasm to the breast masquerading as primary breast cancer: A diagnostic challenge and management dilemma.
Papalampros A, Mpaili E, Moris D, Sarlanis H, Tsoli M, Felekouras E
Medicine (Baltimore). 2019; 98(16):e14989.
PMID: 31008928
PMC: 6494217.
DOI: 10.1097/MD.0000000000014989.
